Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review
Fundamental & Clinical Pharmacology · 2023-12 · 37 (6) · 1139-1152
DOI: 10.1111/fcp.12935 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Fundamental & Clinical Pharmacology, online erschienen am 02.07.2023. Verfasst von Mariana Ferreira-Duarte und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Fundação para a Ciência e a Tecnologia.
Abstract (Originalsprache)
Background
The renin‐angiotensin system (RAS) has been associated with inflammatory bowel disease (IBD), supporting translational relevance of RAS blockers. Comparability of study design/outcomes is fundamental for data analysis/discussion.
Objectives
We aimed at evaluating the heterogeneity among protocols and outcomes to study the effect of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers in IBD.
Methods
This study was performed and reported in accordance with the Cochrane recommendations and PRISMA (PROSPERO‐CRD42022323853). Systematic searches were performed in PubMed, Scopus and Web of Science. Studies that met the inclusion criteria were selected. Quality assessment of the studies was done with the SYRCLES's risk of bias tools for animal studies.
Results
Thirty‐five pre‐clinical studies and six clinical studies were included. Chemical induction of colitis was the most used model, but variable doses of the induction agent were reported. All studies reported at least a disease activity index, a macroscopic score, or a histologic assessment, but these scores were methodologically heterogeneous and reported for different characteristics. Great heterogeneity was also found in drug interventions. Inflammatory markers assessed as outcomes were different across studies.
Conclusion
Lack of standardization of protocols and outcomes among studies threatens the evidence on how RAS blockers influence IBD outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmacology, Department of Drug Sciences, Faculty of Pharmacy, University of Porto, Porto, Portugal.
- LAQV@REQUIMTE, University of Porto, Porto, Portugal.
- ESTeSL-Escola Superior de Tecnologia da Saúde, Instituto Politécnico de Lisboa, Lisbon, Portugal.
- H&TRC-Health and Technology Research Center, Instituto Politécnico de Lisboa, Lisbon, Portugal.
- Department of Immuno-Physiology and Pharmacology, School of Medicine and Biomedical Sciences (ICBAS), University of Porto, Porto, Portugal.
- UCIBIO i4HB - Applied Molecular Biosciences Unit, Faculty of Pharmacy, University of Porto, Porto, Portugal.
ORCID-Profile: Fernando Fernandez-Llimos
Förderung
- Fundação para a Ciência e a Tecnologia
Zitieren
APA
Ferreira-Duarte, M., Tonin, F. S., Duarte-Araújo, M., Fernandez-Llimos, F., & Morato, M. (2023). Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review. Fundamental & Clinical Pharmacology, 37(6), 1139-1152. https://doi.org/10.1111/fcp.12935
Vancouver
Ferreira-Duarte M, Tonin FS, Duarte-Araújo M, Fernandez-Llimos F, Morato M. Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review. Fundamental & Clinical Pharmacology. 2023;37(6):1139-1152. doi:10.1111/fcp.12935
BibTeX
@article{FerreiraDuarte2023,
author = {Ferreira-Duarte, Mariana and Tonin, Fernanda S and Duarte-Araújo, Margarida and Fernandez-Llimos, Fernando and Morato, Manuela},
title = {Heterogeneity in protocols and outcomes to study the effect of renin‐angiotensin system blockers in inflammatory bowel disease: A systematic review},
journal = {Fundamental & Clinical Pharmacology},
year = {2023},
volume = {37},
number = {6},
pages = {1139--1152},
doi = {10.1111/fcp.12935}
}
EUVIMED